Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes

Debbie L. Hay, George Christopoulos, Arthur Christopoulos, David R. Poyner, Patrick M. Sexton

Research output: Contribution to journalArticle

Abstract

Calcitonin (CT) receptors dimerize with receptor activity-modifying proteins (RAMPs) to create high-affinity amylin (AMY) receptors, but there is no reliable means of pharmacologically distinguishing these receptors. We used agonists and antagonists to define their pharmacology, expressing the CT (a) receptor alone or with RAMPs in COS-7 cells and measuring cAMP accumulation. Intermedin short, otherwise known as adrenomedullin 2, mirrored the action of αCGRP, being a weak agonist at CT(a), AMY 2(a), and AMY3(a) receptors but considerably more potent at AMY1(a) receptors. Likewise, the linear calcitonin gene-related peptide (CGRP) analogs (Cys(ACM)2,7)hαCGRP and (Cys(Et) 2,7)haCGRP were only effective at AMY1(a) receptors, but they were partial agonists. As previously observed in COS-7 cells, there was little induction of the AMY2(a) receptor phenotype; thus, AMY 2(a) was not examined further in this study. The antagonist peptide salmon calcitonin8-32 (sCT8-32) did not discriminate strongly between CT and AMY receptors; however, AC187 was a more effective antagonist of AMY responses at AMY receptors, and AC413 additionally showed modest selectivity for AMY1(a) over AMY3(a) receptors. CGRP8-37 also demonstrated receptor-dependent effects. CGRP 8-37 more effectively antagonized AMY at AMY1(a) than AMY3(a) receptors, although it was only a weak antagonist of both, but it did not inhibit responses at the CT(a) receptor. Low CGRP 8-37 affinity and agonism by linear CGRP analogs at AMY 1(a) are the classic signature of a CGRP2 receptor. Our data indicate that careful use of combinations of agonists and antagonists may allow pharmacological discrimination of CT(a), AMY1(a), and AMY3(a) receptors, providing a means to delineate the physiological significance of these receptors. Copyright © 2005 The American Society for Pharmacology and Experimental Therapeutics.

Original languageEnglish
Pages (from-to)1655-1665
Number of pages11
JournalMolecular Pharmacology
Volume67
Issue number5
DOIs
Publication statusPublished - 1 May 2005

Fingerprint

Receptor Activity-Modifying Proteins
Calcitonin Receptors
Islet Amyloid Polypeptide
Islet Amyloid Polypeptide Receptor
Pharmacology
Calcitonin Gene-Related Peptide
COS Cells
Calcitonin
Adrenomedullin
Salmon
Phenotype
Peptides
calcitonin gene-related peptide (8-37)

Keywords

  • amino acid sequence
  • animals
  • COS
  • cells
  • cercopithecus aethiops
  • cyclic AMP
  • dose-response relationship
  • drug
  • humans
  • intracellular signaling
  • peptides
  • membrane
  • proteins
  • molecular sequence data
  • rats receptors
  • calcitonin receptors

Cite this

Hay, Debbie L. ; Christopoulos, George ; Christopoulos, Arthur ; Poyner, David R. ; Sexton, Patrick M. / Pharmacological discrimination of calcitonin receptor : receptor activity-modifying protein complexes. In: Molecular Pharmacology. 2005 ; Vol. 67, No. 5. pp. 1655-1665.
@article{8b373d78838d4ac298e80d29a5d4749f,
title = "Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes",
abstract = "Calcitonin (CT) receptors dimerize with receptor activity-modifying proteins (RAMPs) to create high-affinity amylin (AMY) receptors, but there is no reliable means of pharmacologically distinguishing these receptors. We used agonists and antagonists to define their pharmacology, expressing the CT (a) receptor alone or with RAMPs in COS-7 cells and measuring cAMP accumulation. Intermedin short, otherwise known as adrenomedullin 2, mirrored the action of αCGRP, being a weak agonist at CT(a), AMY 2(a), and AMY3(a) receptors but considerably more potent at AMY1(a) receptors. Likewise, the linear calcitonin gene-related peptide (CGRP) analogs (Cys(ACM)2,7)hαCGRP and (Cys(Et) 2,7)haCGRP were only effective at AMY1(a) receptors, but they were partial agonists. As previously observed in COS-7 cells, there was little induction of the AMY2(a) receptor phenotype; thus, AMY 2(a) was not examined further in this study. The antagonist peptide salmon calcitonin8-32 (sCT8-32) did not discriminate strongly between CT and AMY receptors; however, AC187 was a more effective antagonist of AMY responses at AMY receptors, and AC413 additionally showed modest selectivity for AMY1(a) over AMY3(a) receptors. CGRP8-37 also demonstrated receptor-dependent effects. CGRP 8-37 more effectively antagonized AMY at AMY1(a) than AMY3(a) receptors, although it was only a weak antagonist of both, but it did not inhibit responses at the CT(a) receptor. Low CGRP 8-37 affinity and agonism by linear CGRP analogs at AMY 1(a) are the classic signature of a CGRP2 receptor. Our data indicate that careful use of combinations of agonists and antagonists may allow pharmacological discrimination of CT(a), AMY1(a), and AMY3(a) receptors, providing a means to delineate the physiological significance of these receptors. Copyright {\circledC} 2005 The American Society for Pharmacology and Experimental Therapeutics.",
keywords = "amino acid sequence, animals, COS, cells, cercopithecus aethiops, cyclic AMP, dose-response relationship, drug, humans, intracellular signaling, peptides, membrane, proteins, molecular sequence data, rats receptors, calcitonin receptors",
author = "Hay, {Debbie L.} and George Christopoulos and Arthur Christopoulos and Poyner, {David R.} and Sexton, {Patrick M.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1124/mol.104.008615",
language = "English",
volume = "67",
pages = "1655--1665",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

Pharmacological discrimination of calcitonin receptor : receptor activity-modifying protein complexes. / Hay, Debbie L.; Christopoulos, George; Christopoulos, Arthur; Poyner, David R.; Sexton, Patrick M.

In: Molecular Pharmacology, Vol. 67, No. 5, 01.05.2005, p. 1655-1665.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacological discrimination of calcitonin receptor

T2 - receptor activity-modifying protein complexes

AU - Hay, Debbie L.

AU - Christopoulos, George

AU - Christopoulos, Arthur

AU - Poyner, David R.

AU - Sexton, Patrick M.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Calcitonin (CT) receptors dimerize with receptor activity-modifying proteins (RAMPs) to create high-affinity amylin (AMY) receptors, but there is no reliable means of pharmacologically distinguishing these receptors. We used agonists and antagonists to define their pharmacology, expressing the CT (a) receptor alone or with RAMPs in COS-7 cells and measuring cAMP accumulation. Intermedin short, otherwise known as adrenomedullin 2, mirrored the action of αCGRP, being a weak agonist at CT(a), AMY 2(a), and AMY3(a) receptors but considerably more potent at AMY1(a) receptors. Likewise, the linear calcitonin gene-related peptide (CGRP) analogs (Cys(ACM)2,7)hαCGRP and (Cys(Et) 2,7)haCGRP were only effective at AMY1(a) receptors, but they were partial agonists. As previously observed in COS-7 cells, there was little induction of the AMY2(a) receptor phenotype; thus, AMY 2(a) was not examined further in this study. The antagonist peptide salmon calcitonin8-32 (sCT8-32) did not discriminate strongly between CT and AMY receptors; however, AC187 was a more effective antagonist of AMY responses at AMY receptors, and AC413 additionally showed modest selectivity for AMY1(a) over AMY3(a) receptors. CGRP8-37 also demonstrated receptor-dependent effects. CGRP 8-37 more effectively antagonized AMY at AMY1(a) than AMY3(a) receptors, although it was only a weak antagonist of both, but it did not inhibit responses at the CT(a) receptor. Low CGRP 8-37 affinity and agonism by linear CGRP analogs at AMY 1(a) are the classic signature of a CGRP2 receptor. Our data indicate that careful use of combinations of agonists and antagonists may allow pharmacological discrimination of CT(a), AMY1(a), and AMY3(a) receptors, providing a means to delineate the physiological significance of these receptors. Copyright © 2005 The American Society for Pharmacology and Experimental Therapeutics.

AB - Calcitonin (CT) receptors dimerize with receptor activity-modifying proteins (RAMPs) to create high-affinity amylin (AMY) receptors, but there is no reliable means of pharmacologically distinguishing these receptors. We used agonists and antagonists to define their pharmacology, expressing the CT (a) receptor alone or with RAMPs in COS-7 cells and measuring cAMP accumulation. Intermedin short, otherwise known as adrenomedullin 2, mirrored the action of αCGRP, being a weak agonist at CT(a), AMY 2(a), and AMY3(a) receptors but considerably more potent at AMY1(a) receptors. Likewise, the linear calcitonin gene-related peptide (CGRP) analogs (Cys(ACM)2,7)hαCGRP and (Cys(Et) 2,7)haCGRP were only effective at AMY1(a) receptors, but they were partial agonists. As previously observed in COS-7 cells, there was little induction of the AMY2(a) receptor phenotype; thus, AMY 2(a) was not examined further in this study. The antagonist peptide salmon calcitonin8-32 (sCT8-32) did not discriminate strongly between CT and AMY receptors; however, AC187 was a more effective antagonist of AMY responses at AMY receptors, and AC413 additionally showed modest selectivity for AMY1(a) over AMY3(a) receptors. CGRP8-37 also demonstrated receptor-dependent effects. CGRP 8-37 more effectively antagonized AMY at AMY1(a) than AMY3(a) receptors, although it was only a weak antagonist of both, but it did not inhibit responses at the CT(a) receptor. Low CGRP 8-37 affinity and agonism by linear CGRP analogs at AMY 1(a) are the classic signature of a CGRP2 receptor. Our data indicate that careful use of combinations of agonists and antagonists may allow pharmacological discrimination of CT(a), AMY1(a), and AMY3(a) receptors, providing a means to delineate the physiological significance of these receptors. Copyright © 2005 The American Society for Pharmacology and Experimental Therapeutics.

KW - amino acid sequence

KW - animals

KW - COS

KW - cells

KW - cercopithecus aethiops

KW - cyclic AMP

KW - dose-response relationship

KW - drug

KW - humans

KW - intracellular signaling

KW - peptides

KW - membrane

KW - proteins

KW - molecular sequence data

KW - rats receptors

KW - calcitonin receptors

UR - http://www.scopus.com/inward/record.url?scp=17844365264&partnerID=8YFLogxK

UR - http://molpharm.aspetjournals.org/content/67/5/1655.abstract

U2 - 10.1124/mol.104.008615

DO - 10.1124/mol.104.008615

M3 - Article

C2 - 15692146

VL - 67

SP - 1655

EP - 1665

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -